Protein Production
293FT, 293E, CHO

Truly Functional Protein
95% Purity
1-10 mg in 2 weeks

GeneExpressoMax™
293Expresso™

Transfection Reagents
* 90% Efficiency
* 95% Viability
* No sera interference
* Simple protocol
* High-throughput
* Only $98/ml

Baculovirus
Functional Protein
95% Purity
Fast turnaround
1-10 mg from Sf9 cells

Adenovirus, AAV
& Lentivirus

ORF or shRNA
* High Titer
* Cre, FLP, ΦC31
* Protein Kinases
* Transcription Factors
* Luciferases, GFP, RFP
* Protein Production
* Stable Cell Line


Excellgen

INTEGRATED TREATMENT FOR COMORBID DEPRESSION AND OBESITY IN ADOLESCENTS

Jelalian Elissa
Brown Universitycity: Providence    country: United States (us)

Grant 5R34MH083092-03 from National Institute Of Mental Health

Abstract: Lifetime prevalence of major depression is estimated at 28% by age 18 (Lewinsohn et al., 1999), with higher cumulative rates in females (35%) than males (19%). Approximately 17% of children and adolescents in the United States are obese as defined by a BMI above the 95th percentile, with more than 30% falling between the 85th and 95th percentiles (Ogden et al., 2008). Overweight children and adolescents are at increased risk for type 2 diabetes (Pinhas-Hamiel et al., 1996) and overwhelming risk for adult obesity (Guo et al., 1994). There is a substantial percentage of adolescents who are both overweight and depressed with estimates from clinical samples averaging 25%. Treatment of teens with comorbid medical and psychiatric conditions such as overweight/obesity and depression has received little to no attention in the psychosocial treatment research literature. Due to the large number of adolescents who are both depressed and overweight, developing a behavioral treatment that addresses both problems simultaneously has important public health significance. The purpose of this proposal is to combine treatments for depression and overweight to address these co-occurring conditions in one intervention. The long-term objectives of this research are to develop efficient and effective treatments for co-occurring physical and emotional disorders. The research program will be divided into 3 major phases a development phase (Stage 1a), a pilot study phase (Stage 1b), and a revision phase. During the development phase (Stage 1a), a treatment for overweight teens and CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating. As part of this phase, we will adapt existing intervention manuals and therapist training materials, and gain some initial clinical experience with the intervention via an open trial with 6 teens. During the randomized pilot study phase (Stage 1b), the integrated intervention will be compared to a control group receiving CBT treatment for depression alone (N=40 in total). During the pilot phase, the feasibility and acceptability of administering the program will be assessed. In addition, we will compare change in depressed mood at end of treatment and 6 month follow-up periods across the two groups. During the revision phase, the intervention manual will be further developed and refined, based on experiences and observations made during the development and pilot study phases. The cumulative prevalence of major depression in adolescence is estimated at almost 30%. Similarly, approximately 17% of children and adolescents are obese and another 30% at risk for overweight. This study addresses the co-occurrence of these two major public health issues in adolescence by developing an intervention that addresses both problems in an integrated protocol. The intervention protocol will integrate cognitive-behavioral treatment for depression with exercise plus education about healthy eating to achieve its goals

Keywords: Acute; Address; Adherence (attribute); Adolescence; Adolescent; Adult; Age; Attention; Audiotape; base; Behavior Therapy; Belief; Blood Pressure; Body Weight decreased; Child; Childhood; Cholesterol; Clinical; Cognitive Therapy; Combined Modality Therapy; Comorbidity; Confidence Intervals; Control Groups; Data; Depressed mood; depressive symptoms; Development; Diet Habits; Disease remission; Eating; Educational aspects; effective therapy; Emotional disorder; Exercise; experience; falls; Feasibility Studies; Feedback; Female; follow-up; Gender; Goals; Grant; Guidelines; Health; Individual; Intervention; intervention effect; Interview; Length; Literature; Major Depressive Disorder; male; Manuals; Medical; meetings; Mental Depression; Nature; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Overweight; Parents; Participant; Phase; Physical activity; Pilot Projects; pilot trial; Prevalence; programs; Protocols documentation; psychosocial; public health medicine (field); public health relevance; Randomized; Recruitment Activity; Refractory; Research; Research Personnel; Risk; Running; Sampling; satisfaction; School-Age Population; Series; Staging; Techniques; Teenagers; Testing; Training; Training Programs; Treatment Protocols; United States; Weight; Work

Relevance: Narrative The cumulative prevalence of major depression in adolescence is estimated at almost 30%. Similarly, approximately 17% of children and adolescents are obese and another 30% at risk for overweight. This study addresses the co-occurrence of these two major public health issues in adolescence by developing an intervention that addresses both problems in an integrated protocol. The intervention protocol will integrate cognitive-behavioral treatment for depression with exercise plus education about healthy eating to achieve its goals

Project start date: 2009-12-01

Project end date: 2012-11-30

Budget start date: 1-DEC-2011

Budget end date: 30-NOV-2012

5R34MH083092-03 (2012): $208901


Sponsored Links Excellgen http://Excellgen.com

Recombinant Lentivirus & Adenovirus
High Yield and High Titer up to 1010 (lentivirus) and 1013 (adenovirus) for Guaranteed Expression of GOI. $3000, $2500
Baculovirus Protein Expression
Fast turn around, >95% purity functional protein. No outsourcing to China or India. $5500, $3950
Transient Protein Expression in CHO and HEK293 Cells
Transient Expression, Truly Functional Protein, 95% purity, 1~20 mg, fast turnaround. $5500, $3950